Madrigal Pharmaceuticals Executive and Leadership Team

Bill Sibold, the Chief Executive Officer at Madrigal Pharmaceuticals, directs the overarching corporate strategy and clinical development roadmap. Overseeing the advancement of MGL-3196, the Chief Executive Officer ensures alignment between research milestones and long-term commercialization goals. This leadership role involves managing investor relations and securing the capital necessary for Phase II clinical trials. By fostering partnerships across the global biopharmaceutical landscape, Bill Sibold expands the reach of liver-directed therapeutic candidates. The Chief Executive Officer maintains a focus on operational excellence, ensuring that the organization remains agile while navigating complex regulatory environments. Through rigorous oversight of the pipeline, Sibold drives the company toward delivering novel treatments for non-alcoholic steatohepatitis and hypercholesterolemia. Ultimately, the Chief Executive Officer secures the future of the enterprise by prioritizing scientific integrity and sustainable growth within the competitive cardiovascular and metabolic disease sectors.

Clint Wallace, the Executive Vice President & Chief Human Resources Officer at Madrigal Pharmaceuticals, architects the talent acquisition and organizational development strategies required to support clinical-stage operations. Overseeing the recruitment of specialized scientific personnel, the Executive Vice President & Chief Human Resources Officer ensures the company maintains a high-performance culture. This leadership role involves designing compensation structures that attract top-tier researchers and clinical experts. By implementing robust training programs, Clint Wallace fosters an environment of continuous learning and innovation. The Executive Vice President & Chief Human Resources Officer manages internal communications and employee engagement initiatives to align the workforce with the mission of treating liver diseases. Through strategic workforce planning, Wallace supports the scaling of operations as the company transitions toward commercialization. Ultimately, the Executive Vice President & Chief Human Resources Officer builds the human infrastructure necessary to sustain long-term success in the demanding pharmaceutical industry.

Ronald Filippo, the Executive Vice President & Chief Information Officer at Madrigal Pharmaceuticals, directs the digital transformation and data management strategies essential for clinical trial success. Overseeing the secure integration of complex medical datasets, the Executive Vice President & Chief Information Officer ensures compliance with global data privacy standards. This leadership role involves architecting scalable cloud infrastructure to support the analysis of MGL-3196 trial results. By deploying advanced analytics tools, Ronald Filippo enables the research teams to interpret metabolic and cardiovascular data with precision. The Executive Vice President & Chief Information Officer manages the cybersecurity framework protecting proprietary intellectual property and patient information. Through the implementation of robust IT systems, Filippo supports the seamless collaboration between clinical sites and internal research departments. Ultimately, the Executive Vice President & Chief Information Officer drives the technological capabilities required to accelerate the development of life-saving liver-directed therapies.

David Soergel, the Executive Vice President & Chief Medical Officer at Madrigal Pharmaceuticals, directs the clinical development programs and medical strategy for the company's lead candidate, MGL-3196. Overseeing the design and execution of Phase II clinical trials, the Executive Vice President & Chief Medical Officer ensures that all research meets rigorous scientific and regulatory standards. This leadership role involves collaborating with global health authorities to validate the efficacy of thyroid hormone receptor agonists. By analyzing clinical outcomes, David Soergel guides the therapeutic direction for patients suffering from non-alcoholic steatohepatitis. The Executive Vice President & Chief Medical Officer manages the medical affairs team to communicate trial findings to the broader scientific community. Through deep expertise in metabolic disease, Soergel drives the clinical validation process. Ultimately, the Executive Vice President & Chief Medical Officer ensures that the company delivers safe and effective treatments to address significant unmet medical needs.

Shannon Kelley, the Executive Vice President & Chief Legal Officer at Madrigal Pharmaceuticals, directs the legal strategy and intellectual property protection for the company's portfolio of therapeutic candidates. Overseeing the management of complex regulatory filings, the Executive Vice President & Chief Legal Officer ensures full compliance with pharmaceutical industry laws. This leadership role involves negotiating strategic partnerships and licensing agreements that support the commercialization of MGL-3196. By mitigating legal risks, Shannon Kelley safeguards the company's assets and research investments. The Executive Vice President & Chief Legal Officer manages corporate governance and board relations to ensure transparency and ethical conduct. Through proactive legal counsel, Kelley supports the organization in navigating the intricacies of clinical-stage development. Ultimately, the Executive Vice President & Chief Legal Officer provides the foundational legal framework that allows the company to focus on its mission of developing innovative treatments for liver and metabolic diseases.